gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity
摘要:
New diphosphonate compounds and related derivatives were synthesized and investigated for their activity in specifically inducing plasma high density lipoproteins (HDL) and high density lipoprotein cholesterol (HDL-C) in normal rats. The screening of numerous compounds has permitted the determination of the structural variations leading to optimal plasma lipid altering activity, indicating antiatherosclerotic potential. Among the compounds observed to be the most active, dimethyl alpha-(dimethoxyphosphinyl)-p-chlorobenzyl phosphate (20, SR-202, mifobate) was selected for further pharmacological and subsequent clinical development.
NGUYEN, LAN M.;NIESOR, ERIC;BENTZEN, CRAIG L., J. MED. CHEM., 30,(1987) N 8, 1426-1433
作者:NGUYEN, LAN M.、NIESOR, ERIC、BENTZEN, CRAIG L.
DOI:——
日期:——
Knoevenagel kondensationen mit TiCl4/base-IV
作者:W. Lehnert
DOI:10.1016/s0040-4020(01)91461-9
日期:1974.1
In the presence of titanium tetrachloride and an organic base in tetrahydrofurane, triethyl phosphonoacetic acid undergoes condensation with aliphatic and aromatic aldehydes and aromatic ketones to yield the corresponding triethyl alkylidene and arylidene phosphonoacetic acids respectively. Tetraalkyl methylenediphosphonates and aromatic or aliphatic α-branched aldehydes react under identical conditions
gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity
作者:Nguyen Lan Mong、Eric Niesor、Craig L. Bentzen
DOI:10.1021/jm00391a027
日期:1987.8
New diphosphonate compounds and related derivatives were synthesized and investigated for their activity in specifically inducing plasma high density lipoproteins (HDL) and high density lipoprotein cholesterol (HDL-C) in normal rats. The screening of numerous compounds has permitted the determination of the structural variations leading to optimal plasma lipid altering activity, indicating antiatherosclerotic potential. Among the compounds observed to be the most active, dimethyl alpha-(dimethoxyphosphinyl)-p-chlorobenzyl phosphate (20, SR-202, mifobate) was selected for further pharmacological and subsequent clinical development.